Company code: Shanghai Haoyuan Chemexpress Co.Ltd(688131) company abbreviation: Shanghai Haoyuan Chemexpress Co.Ltd(688131) Shanghai Haoyuan Chemexpress Co.Ltd(688131)
Annual report for 2021
Important tips
1、 The board of directors, board of supervisors, directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and integrity of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 2、 The company is not profitable and has not achieved profitability when it is listed □ yes √ no III. Major Risks suggest that the company has described in detail various risks and countermeasures that the company may face in the process of production and operation in this report. Please refer to "IV. risk factors" in "section III Management Discussion and analysis". Investors are kindly requested to pay attention and pay attention to investment risks. 4、 All directors of the company attended the board meeting. 5、 Rongcheng Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 6、 Zheng Baofu, the person in charge of the company, Li Min, the person in charge of accounting, and Li Min, the person in charge of the accounting organization (Accounting Supervisor), declare that they guarantee the authenticity, accuracy and completeness of the financial report in the annual report. 7、 The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
According to the strategic planning and business development needs, and on the premise of ensuring the normal capital needs of the company, the company plans to distribute a cash dividend of 5.30 yuan (including tax) to all shareholders for every 10 shares. Based on the total share capital of 74342007 shares as of December 31, 2021, the total cash dividend to be distributed is 3940126371 yuan (including tax). The proportion of cash dividends of the company in this year accounts for 20.63% of the net profit attributable to the shareholders of the company. At the same time, the company plans to increase 4 shares for every 10 shares to all shareholders with capital reserve. Based on the total share capital of 74342007 shares as of December 31, 2021, a total of 29736802 shares will be increased. After the increase, the total share capital of the company will be increased to 104078809 shares. The number of converted shares is the company's rounding income according to the actual calculation results. The final number of converted shares is subject to the number of shares disclosed in the announcement on the implementation of equity distribution issued separately after the company has completed the legal procedures.
The above profit distribution plan has been deliberated and adopted at the fifth meeting of the third board of directors and the fifth meeting of the third board of supervisors. The independent directors have expressed their independent opinions on this plan, which needs to be approved by the 2021 annual general meeting of shareholders of the company. 8、 Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable IX. risk statement of forward-looking statements √ applicable □ not applicable to forward-looking statements such as the company's future plan and development strategy involved in this report, which does not constitute the company's substantive commitment to investors. Investors are invited to pay attention to investment risks.
10、 Whether there is any non operational occupation of funds by the controlling shareholders and their related parties no Xi. Whether there is any external guarantee in violation of the specified decision-making procedures no XII. Whether more than half of the directors cannot guarantee the authenticity, accuracy and completeness of the annual report disclosed by the company no XIII. Others □ applicable √ not applicable
catalogue
Section 1 interpretation Section 2 company profile and main financial indicators Section III Management Discussion and Analysis Section IV corporate governance 58 Section V environment, social responsibility and other corporate governance 75 section VI important matters Section VII changes in shares and shareholders Section VIII preferred shares 118 section IX relevant information of corporate bonds 119 section x financial report one hundred and nineteen
Financial statements containing the signatures and seals of the person in charge of the company, the person in charge of accounting work and the person in charge of accounting organization (Accounting Supervisor)
The catalogue of documents for future reference contains the original audit report sealed by the accounting firm and signed and sealed by the certified public accountant
The originals of all company documents and announcements publicly disclosed on the website designated by the CSRC during the reporting period
Section I interpretation
1、 Interpretation in this report, unless the context otherwise requires, the following words have the following meanings: Interpretation of common words
The company refers to Shanghai Haoyuan Chemexpress Co.Ltd(688131)
Shanghai Haoyuan Chemexpress Co.Ltd(688131)
Haoyuan biology refers to Shanghai Haoyuan Biomedical Technology Co., Ltd., which is a wholly-owned subsidiary of the company
Haohong biology refers to Shanghai Haohong Biomedical Technology Co., Ltd., which is a wholly-owned subsidiary of the company
Kaixin biology refers to Shanghai Kaixin Biomedical Technology Co., Ltd., which is a wholly-owned subsidiary of the company
Anhui Haoyuan refers to Anhui Haoyuan Pharmaceutical Co., Ltd., which is a wholly-owned subsidiary of the company
Hong Kong Haoyuan refers to Haoyuan Technology Development Co., Ltd., which is a wholly-owned subsidiary of the company
MCE refers to medchemexpress LLC, a wholly-owned subsidiary of Hong Kong Haoyuan
CS refers to chemscene limited license company, a wholly-owned subsidiary of Hong Kong Haoyuan
Anhui Leyan refers to Anhui Leyan Biomedical Technology Co., Ltd., which is a wholly-owned subsidiary of Haohong biology
Gansu Haotian refers to Gansu Haotian Chemical Technology Co., Ltd., which is a joint-stock company of the company
Haotian pharmaceutical refers to Gansu Haotian Pharmaceutical Technology Co., Ltd., which is a wholly-owned subsidiary of Gansu Haotian
Zhenhao biotechnology refers to Shanghai Zhenhao Biotechnology Co., Ltd., which is a joint-stock company of the company
Hezheng medicine refers to Hangzhou Hezheng Medicine Co., Ltd., which is a joint-stock company of the company
Anshu information refers to Shanghai Anshu Information Technology Co., Ltd
Ouchuang gene refers to Hefei ouchuang gene Biotechnology Co., Ltd
Yantai Haoyuan refers to Yantai Haoyuan Biomedical Technology Co., Ltd
Jinglide refers to Nanjing jinglide Technology Co., Ltd
Sumin fund refers to Sumin Junxin (Shanghai) industrial upgrading and scientific and technological innovation equity investment partnership (limited partnership)
Zhenjin investment refers to Shanghai Zhenjin high tech service industry venture capital center (limited partnership)
Jingjia venture refers to Shanghai Jingjia venture relay venture capital center (limited partnership)
Huyue yongwo refers to Hangzhou Huyue yongwo investment management partnership (limited partnership)
It refers to organic compounds commonly known as chemical synthetic drugs, usually with molecular weight less than 1000, that is, special chemicals with clear chemical structure that can prevent, treat and diagnose diseases, or to regulate human function, improve small molecule drugs, improve quality of life and maintain health.
Chemical synthetic drugs take small molecular compounds as their material basis and the efficacy (biological effect) of drug efficacy as their application basis. Small molecule drugs have the advantages of wide use and mature theory.
It refers to the small molecular compounds used to design and construct drug active substances for research and development. It is one of the important materials for drug research and development. Generally, the molecular weight is less than 300. It has the characteristics of novel structure, variety and so on.
It refers to small molecular compounds with certain biological or pharmacological activities whose synthesis path is at the back end of molecular blocks, which are widely used in the early stage of life science and pharmaceutical research. Researchers use tool compounds to observe and study the physiological and pathological phenomena in the life process at the molecular level, cell level and animal model level by changing or affecting the structure, function and action mechanism of biological macromolecules such as protein and nucleic acid, so as to reveal the law of life and the occurrence and development process of diseases. The composition of the tool compound in the drug development stage corresponds to the API in the drug production stage.
It refers to active pharmaceutical ingredient, also known as active pharmaceutical ingredient, which is prepared by chemical synthesis, API plant extraction or biotechnology, but can not be taken directly by patients. Generally, it is made into directly usable drugs after adding excipients and processing. It is the raw material of drugs.
Pharmaceutical intermediates refer to some chemical raw materials or chemical products used in the process of drug synthesis. This chemical intermediate product can be produced in an ordinary chemical plant without a drug production license. As long as it reaches a certain level, it can be used for drug synthesis.
Innovative drugs refer to drugs that are first listed in the world and have independent intellectual property rights and patents.
It refers to a generic drug that is the same as the innovative drug in terms of dose, safety, efficacy, quality, effect and indication. This report specifically refers to the drugs developed based on the drugs that have been listed and whose patents have expired.
Tool molecular library refers to the collection of a large number of tool molecules, which are often used to realize high-throughput screening and operation, and are used for new drug research and development and the exploration of new indications.
Compound library refers to a library composed of a large number of compounds.
It refers to antibody drug conjugate. It is composed of monoclonal antibody, small molecule ADC, ADC drug and linker connecting the two. ADC is targeted and recognized by monoclonal antibody and enters tumor cells, releases effective chemotherapeutic drugs in tumor cells and kills tumor cells
Proteolysis targeting chimera is a bifunctional small molecule, which is obtained by linking the target protein ligand protac and E3 ubiquitin ligase ligand through linker. It uses ubiquitin protease system to recognize, bind and degrade disease-related target proteins, so as to achieve the effect of disease treatment.
Linker library refers to a chain tool molecule connecting two functional molecules, which can be used to synthesize ADC or protac. Linker library is a tool molecular library composed of multiple linker molecules.
Toxin linker library refers to a tool molecular library composed of multiple molecules of toxin and linker.
Refers to the contractresearch organization, a customized R & D organization, which mainly provides new drug R & D contract services such as preclinical drug discovery, preclinical research and clinical trials for multinational pharmaceutical enterprises, cro industry and biopharmaceutical companies.
Refers to the contractmanufacturing organization, a pharmaceutical contract customized production enterprise, which refers to an organization that provides large-scale / customized production services of pharmaceutical products for CMO pharmaceutical enterprises and biotechnology companies. Its R & D technology generally relies on the mature process route provided by customers, uses its own production facilities for process implementation, and provides expanded production services.
Refers to the contract development and manufacturing organization, a pharmaceutical contract customized R & D and production enterprise, which provides pharmaceutical enterprises and biotechnology companies with medicine, especially cdmo new drug process research and development and small batch preparation; Process optimization, scale-up production, registration and verification of batch production; Commercial production and other services. CDMO
